風範股份(601700.SH):風範晶櫻擬與唐控科創共同對康達錦瑞進行增資
格隆匯7月9日丨風範股份(601700.SH)公佈,風範股份全資子公司風範晶櫻擬與公司關聯方唐控科創共同對康達新材料(集團)股份有限公司(稱“康達新材”)之全資孫公司康達錦瑞進行增資。合計增資人民幣11,666.67萬元,其中,唐控科創以現金方式增資人民幣6,666.67萬元,增資後持有康達錦瑞40%的股權;風範晶櫻以現金增資人民幣5,000.00萬元,增資後持有康達錦瑞30%的股權。
本次增資完成後,康達錦瑞的註冊資本將由人民幣5,000.00萬元增至人民幣16,666.67萬元。公司持有康達錦瑞的股權比例為30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.